Clinical trials: Pyoderma Gangrenosum
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Diabetic Foot, Pressure Ulcer
A Real-World Registry of Chronic Wounds and Ulcers
WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis
- Trial name
- WOUNDJOURNEY (NCT02280733)
- Testing
- Usual care
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- U.S. Wound Registry
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Solid Tumors
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
- Trial name
- NCT03386942
- Testing
- Farletuzumab Ecteribulin
- Where
- 10 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Pyoderma Gangrenosum
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum is a chronic debilitating ulcerative neutrophilic condition usually affecting the skin. The pathogenesis of pyoderma gangrenosum is poorly understood.
- Trial name
- NCT05120726
- Testing
- Dehydrated human amnion/chorion membrane
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Pyoderma Gangrenosum
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers.
- Trial name
- TRIUMPH (NCT07783412)
- Testing
- topical ruxolitinib 1.5% cream
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal antibodies.
- Trial name
- NCT04274166
- Testing
- secukinumab 150 mg (2 injections per dose
- Sponsor
- Wake Forest University Health Sciences
Pyoderma Gangrenosum
Canakinumab for Pyoderma Gangrenosum
This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.
- Trial name
- NCT01302795
- Testing
- Canakinumab
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University of Zurich
Pyoderma Gangrenosum
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
- Trial name
- NCT07444684
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02315417
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
- Trial name
- NCT03072953
- Testing
- APD334
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Arena Pharmaceuticals
Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
- Trial name
- NCT05964413
- Testing
- vilobelimab
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma…
- Trial name
- NCT02733094
- Testing
- Secukinumab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Technical University of Munich
Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, which makes the diagnosis…
- Trial name
- NCT04750213
- Where
- 46 sites in Japan
- Volunteers
- 60 people
- Sponsor
- AbbVie
Pyoderma Gangrenosum
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
- Trial name
- NCT02318914
- Testing
- gevokizumab
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
Deucravacitinib in PG
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
- Trial name
- NCT05821374
- Testing
- Deucravacitinib
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pyoderma Gangrenosum, Hidradenitis Suppurativa
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG).
- Conditions
- Pyoderma Gangrenosum, Hidradenitis Suppurativa, Psoriasis
- Trial name
- NCT04792957
- Testing
- immunohistochemical methods
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University